Snake venom thrombin-like enzyme (SVTLE)

Snake venom thrombin-like enzymes (SVTLEs) are specialized serine proteases derived from the venom of Viperidae snakes that functionally mimic the human enzyme thrombin (PMID: 15603530). While physiological thrombin cleaves both fibrinopeptide A and B to create a stable, cross-linked fibrin clot, SVTLEs typically cleave only one of these peptides, leading to the formation of friable, non-crosslinked fibrin polymers (UniProt: P04971). These unstable polymers are efficiently removed by the body's natural fibrinolytic mechanisms, which paradoxically leads to a state of systemic defibrinogenation and potent anticoagulation. Therapeutically, these enzymes have been developed as defibrinogenating agents to treat conditions like acute ischemic stroke, deep vein thrombosis, and peripheral arterial occlusion by lowering blood viscosity and preventing thrombus extension (PMID: 11512031). They are also used as diagnostic reagents, such as in the Reptilase time test, to assess fibrinogen conversion without interference from heparin. Despite their efficacy, their clinical use is limited by the risk of severe bleeding and the potential for neutralizing antibody production due to their non-human origin. Monitoring of plasma fibrinogen levels is essential during therapy to maintain a balance between therapeutic anticoagulation and the risk of hemorrhage.

Other names

Snake venom serine proteaseSVSPFibrinogenaseThrombin-like enzymeBatroxobinAncrodCrotalaseReptilaseDefibrinogenating enzyme

SVTLEs cleave fibrinogen to release either fibrinopeptide A or B (but rarely both), producing unstable fibrin monomers that fail to cross-link and are rapidly cleared by the endogenous fibrinolytic system, resulting in therapeutic defibrinogenation.